The NetworkNewsAudio Interviews Podcast

ev Transportation Services (“evTS”) is a specialty vehicle OEM that produces purpose built, all-electric lightweight commercial utility vehicles and fleet management solutions. The Boston-based company is currently focused on the essential services transportation and urban mobility markets, which represent an annual domestic replacement market of approximately 100,000 vehicles, or roughly $2.5 billion annually. End-user applications for the company's vehicles include, among others, parking enforcement, security patrol, utility meter reading, property and building management, sanitation, airports, seaports, university and corporate campuses, warehouses and fulfilment, and last mile on-demand urban delivery. For more information, visit the company's website at www.evTS.com.

ev Transportation Services (“evTS”) is a specialty vehicle OEM that produces purpose built, all-electric lightweight commercial utility vehicles and fleet management solutions. The Boston-based company is currently focused on the essential services transportation and urban mobility markets, which represent an annual domestic replacement market of approximately 100,000 vehicles, or roughly $2.5 billion annually. End-user applications for the company's vehicles include, among others, parking enforcement, security patrol, utility meter reading, property and building management, sanitation, airports, seaports, university and corporate campuses, warehouses and fulfilment, and last mile on-demand urban delivery. For more information, visit the company's website at www.evTS.com.

Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America's key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels' common shares is the NYSE American under the trading symbol “UUUU,” and the company's common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.”

Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America's key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels' common shares is the NYSE American under the trading symbol “UUUU,” and the company's common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.”

LOS ANGELES (December 16, 2020) – via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), recently appeared on the Want Money Got Money Podcast, a series that helps entrepreneurs learn from the stories, secrets and skills of the world's most brilliant and interesting startup founders and investors. The podcast, hosted by Author, Founder, Speaker and CEO Sam Kamani, is available for on-demand listening at https://samkamani.buzzsprout.com. During the interview, Climaco discussed the research of CNS Pharmaceuticals founder Dr. Waldemar Priebe into the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. He also provided an overview of the company's lead drug candidate, Berubicin, which is proposed for the treatment of GBM. Berubicin has been evaluated in a Phase I clinical trial, where 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS has applied to the U.S. Food and Drug Administration to begin a Phase II clinical trial and expects to begin enrolling patients in this trial in the first quarter of 2021. 

LOS ANGELES (December 16, 2020) – via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, Chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), recently appeared on the Want Money Got Money Podcast, a series that helps entrepreneurs learn from the stories, secrets and skills of the world's most brilliant and interesting startup founders and investors. The podcast, hosted by Author, Founder, Speaker and CEO Sam Kamani, is available for on-demand listening at https://samkamani.buzzsprout.com. During the interview, Climaco discussed the research of CNS Pharmaceuticals founder Dr. Waldemar Priebe into the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. He also provided an overview of the company's lead drug candidate, Berubicin, which is proposed for the treatment of GBM. Berubicin has been evaluated in a Phase I clinical trial, where 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS has applied to the U.S. Food and Drug Administration to begin a Phase II clinical trial and expects to begin enrolling patients in this trial in the first quarter of 2021. 

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP's chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. As a result of the trial, 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS recently submitted an Investigational New Drug (“IND”) application with the FDA, and, pending approval, it intends to commence a pivotal Phase II clinical trial in the U.S. “I have done all kinds of different things in my career, been in the health care industry for a long time. This is the most exciting thing that I've done,” Climaco said in the interview. “This company and our lead product have the potential to really change the landscape and the game in an area of oncology that hasn't seen a lot of hope for a very long time in glioblastoma.” To view the full press release, visit https://nnw.fm/jfjZB   CNS Pharmaceuticals (NASDAQ: CNSP) is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. 

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP's chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. As a result of the trial, 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS recently submitted an Investigational New Drug (“IND”) application with the FDA, and, pending approval, it intends to commence a pivotal Phase II clinical trial in the U.S. “I have done all kinds of different things in my career, been in the health care industry for a long time. This is the most exciting thing that I've done,” Climaco said in the interview. “This company and our lead product have the potential to really change the landscape and the game in an area of oncology that hasn't seen a lot of hope for a very long time in glioblastoma.” To view the full press release, visit https://nnw.fm/jfjZB   CNS Pharmaceuticals (NASDAQ: CNSP) is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. 

Gage Cannabis is a premium adult-use cannabis retailer in Ayer, Massachusetts with a mission to provide customers with a diverse selection of the best cannabis and cannabis-infused products available in Massachusetts. For more information, visit the company's website at www.GageCannabisCo.com.

Pac Roots (CSE: PACR) is focused on delivering the finest genetics to Canadians. Preserving the excellence of its elite strains while introducing the highest quality of new strains to the public is the company's passion. The foundation, based on genetic variation and stability, drives the decision making for Pac Roots Cannabis Corp.'s business.

Gage Cannabis is a premium adult-use cannabis retailer in Ayer, Massachusetts with a mission to provide customers with a diverse selection of the best cannabis and cannabis-infused products available in Massachusetts. For more information, visit the company's website at www.GageCannabisCo.com.

Pac Roots (CSE: PACR) is focused on delivering the finest genetics to Canadians. Preserving the excellence of its elite strains while introducing the highest quality of new strains to the public is the company's passion. The foundation, based on genetic variation and stability, drives the decision making for Pac Roots Cannabis Corp.'s business.

GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF) is a Canadian junior exploration company active in the Maricunga Gold Belt of Northern Chile. The Maricunga measures 150 km north-south and 30 km. east-west and is host to discoveries in the last 10 years of 100M oz. gold; 450M oz. silver and 1.3 billion lbs. copper. The company has agreements in place to acquire seven projects with extensive surface study. GoldHaven has identified four of its seven properties as “high-priority targets,” three of which the company plans to drill commencing January 2021. These priority targets were designated as such due, first, to the analytical work that has been completed on all the properties and, second, to their relative locations in respect to existing deposits. One such existing project is Coya, located approximately 16 km. northeast of the La Coipa mine, where Kinross extracted over 6.2 million oz. Other existing projects include Rio Loa and Alicia, which are respectively 25 km. and 30 km. distance from GoldHaven's Salares Norte deposit with a discovery of 5M oz. gold, 450M oz. silver and 1.3B lbs. copper.

GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF) is a Canadian junior exploration company active in the Maricunga Gold Belt of Northern Chile. The Maricunga measures 150 km north-south and 30 km. east-west and is host to discoveries in the last 10 years of 100M oz. gold; 450M oz. silver and 1.3 billion lbs. copper. The company has agreements in place to acquire seven projects with extensive surface study. GoldHaven has identified four of its seven properties as “high-priority targets,” three of which the company plans to drill commencing January 2021. These priority targets were designated as such due, first, to the analytical work that has been completed on all the properties and, second, to their relative locations in respect to existing deposits. One such existing project is Coya, located approximately 16 km. northeast of the La Coipa mine, where Kinross extracted over 6.2 million oz. Other existing projects include Rio Loa and Alicia, which are respectively 25 km. and 30 km. distance from GoldHaven's Salares Norte deposit with a discovery of 5M oz. gold, 450M oz. silver and 1.3B lbs. copper.

Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. After offering some brief insight into the operations of Skyline Medical, Schwartz turned his attention toward TumorGenesis. “TumorGenesis is an interesting company. The whole purpose of it was to develop a lab media to replace rats and mice in the scientific industries and in the testing of tumors,” he stated in the interview. “They have developed the first one, which is ovarian cancer, and the results of this are that this media, which, as I said, replicates the body, fools the tumor into thinking it's still in the body. Its reactions are very, very similar to what it would have done had it been in the body. Now, the next step is to get it positioned to manufacturers and getting the kits out so people can use it. That's coming along handsomely. It'll take a little time to get all this put in place, but the optimism is there, and the results are wonderful. We're very excited.”

Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. After offering some brief insight into the operations of Skyline Medical, Schwartz turned his attention toward TumorGenesis. “TumorGenesis is an interesting company. The whole purpose of it was to develop a lab media to replace rats and mice in the scientific industries and in the testing of tumors,” he stated in the interview. “They have developed the first one, which is ovarian cancer, and the results of this are that this media, which, as I said, replicates the body, fools the tumor into thinking it's still in the body. Its reactions are very, very similar to what it would have done had it been in the body. Now, the next step is to get it positioned to manufacturers and getting the kits out so people can use it. That's coming along handsomely. It'll take a little time to get all this put in place, but the optimism is there, and the results are wonderful. We're very excited.”  

Founded in 2012, The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company's CBD water and flavor-infused water. For the company's topical and ingestible offerings, A88 Infused Products includes both the company's lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies.

Founded in 2012, The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company's CBD water and flavor-infused water. For the company's topical and ingestible offerings, A88 Infused Products includes both the company's lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies.

Cybin Corp. is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.

Cybin Corp. is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.

ISW Holdings (OTC: ISWH), based in Nevada, is a diversified portfolio company comprised of essential business lines that serve consumer product demands. Its expertise lies in strategic brand development, early growth facilitation, as well as brand identity through the company's proprietary procurement process. Together with its partners, ISW Holdings seeks to provide a structure that meets large scalability demands as well as anticipated marketplace needs. It is able to meet these needs through a variety of strategic, innovative processes. ISWH is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which include conceptualization, go-to-market strategies, engineering, product integration, and distribution efficiency. The company has also partnered with a well-known software development and consulting company, Bengala Technologies LLC, which is developing significant enhancements in the supply chain management space; the partnership has a vitally needed patent pending.

ISW Holdings (OTC: ISWH), based in Nevada, is a diversified portfolio company comprised of essential business lines that serve consumer product demands. Its expertise lies in strategic brand development, early growth facilitation, as well as brand identity through the company's proprietary procurement process. Together with its partners, ISW Holdings seeks to provide a structure that meets large scalability demands as well as anticipated marketplace needs. It is able to meet these needs through a variety of strategic, innovative processes. ISWH is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which include conceptualization, go-to-market strategies, engineering, product integration, and distribution efficiency. The company has also partnered with a well-known software development and consulting company, Bengala Technologies LLC, which is developing significant enhancements in the supply chain management space; the partnership has a vitally needed patent pending.

PowerBand Solutions (TSX.V: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA) is a fintech provider disrupting the automotive industry. PowerBand's integrated, cloud-based transaction platform facilitates transactions amongst consumers, dealers, funders and manufacturers (“OEMs”). It enables them to buy, sell, trade, finance, and lease new and used, electric- and non-electric vehicles, on smart phones or any other online digital devices, from any location. PowerBand's transaction platform – being trademarked under DRIVRZ – is being made available across North American and global markets.

National Storm Recovery (OTC: NSRI), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company and its Sustainable Green Team's solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through the company's tree services division and collection sites, and then, through the company's processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and are positioned for rapid growth from the resulting synergistic opportunities identified. The company's customers include governmental, residential and commercial clients.

National Storm Recovery (OTC: NSRI), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company and its Sustainable Green Team's solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through the company's tree services division and collection sites, and then, through the company's processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and are positioned for rapid growth from the resulting synergistic opportunities identified. The company's customers include governmental, residential and commercial clients.

The Movie Studio (OTC: MVES) operates as a vertically integrated motion-picture production and distribution company. The company acquires, develops, produces and distributes independent motion-picture content for worldwide consumption via theatrical release, video on demand, foreign sales and various media devices. MVES is disrupting traditional media-content delivery systems with its digital business model of motion picture distribution. The company was formerly known as Destination Television Inc. and changed its name to The Movie Studio Inc. in November 2012. The Movie Studio Inc. was founded in 1961 and is headquartered in Fort Lauderdale, Florida.

The Movie Studio (OTC: MVES) operates as a vertically integrated motion-picture production and distribution company. The company acquires, develops, produces and distributes independent motion-picture content for worldwide consumption via theatrical release, video on demand, foreign sales and various media devices. MVES is disrupting traditional media-content delivery systems with its digital business model of motion picture distribution. The company was formerly known as Destination Television Inc. and changed its name to The Movie Studio Inc. in November 2012. The Movie Studio Inc. was founded in 1961 and is headquartered in Fort Lauderdale, Florida.

Bullfrog Gold (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) is a Delaware corporation that controls the commanding land and mineral positions in the Bullfrog Mine area. In this area, Barrick produced 2.3 million ounces of gold through conventional milling beginning in 1989 and ending in 1999.

Exro Technologies (CSE: XRO) (OTCQB: EXROF) is a Clean Tech company that has developed a new class of control technology for electric powertrains. Exro's advanced motor control technology, its “Coil Driver,” expands the capabilities of electric motors and powertrains. The Coil Driver enables two separate torque profiles within a given motor. The first is calibrated for low speed and high torque, while the second provides expanded operation at high speed. The ability to change configuration allows efficiency optimization for each operating mode, resulting in overall reductions in energy consumption. The controller automatically and seamlessly selects the appropriate configuration in real-time so that torque demand and efficiency are optimized.

Sigma Labs (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D(R) brand. Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs' advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time.

Bullfrog Gold (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) is a Delaware corporation that controls the commanding land and mineral positions in the Bullfrog Mine area. In this area, Barrick produced 2.3 million ounces of gold through conventional milling beginning in 1989 and ending in 1999.

Exro Technologies (CSE: XRO) (OTCQB: EXROF) is a Clean Tech company that has developed a new class of control technology for electric powertrains. Exro's advanced motor control technology, its “Coil Driver,” expands the capabilities of electric motors and powertrains. The Coil Driver enables two separate torque profiles within a given motor. The first is calibrated for low speed and high torque, while the second provides expanded operation at high speed. The ability to change configuration allows efficiency optimization for each operating mode, resulting in overall reductions in energy consumption. The controller automatically and seamlessly selects the appropriate configuration in real-time so that torque demand and efficiency are optimized.

Sigma Labs (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D(R) brand. Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs' advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time.

Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S,-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America's key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the United States today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S., including several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels' common shares is the NYSE American under the trading symbol UUUU; the company's common shares are also listed on the Toronto Stock Exchange under the trading symbol EFR.

Energy Fuels (NYSE American: UUUU) (TSX: EFR) is a leading U.S,-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America's key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the United States today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S., including several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels' common shares is the NYSE American under the trading symbol UUUU; the company's common shares are also listed on the Toronto Stock Exchange under the trading symbol EFR.

National Storm Recovery (OTC: NSRI), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company and its Sustainable Green Team's solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then through processing, recycling and using that tree debris as feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic-growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. NSRI serves governmental, residential and commercial customers.

National Storm Recovery (OTC: NSRI), through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company and its Sustainable Green Team's solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then through processing, recycling and using that tree debris as feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic-growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. NSRI serves governmental, residential and commercial customers.

Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other) that contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics' CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients' specific needs. Predictive Oncology's TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform Kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis' Oncology Capture Technology Platforms, which isolate and help categorize an individual patient's heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology's Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.

Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other) that contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics' CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients' specific needs. Predictive Oncology's TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform Kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis' Oncology Capture Technology Platforms, which isolate and help categorize an individual patient's heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology's Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.

Champignon Brands (CSE: SHRM) has positioned itself to rapidly become a global force as a vertically integrated producer of artisanal medicinal mushrooms and associated products. The Champignon team is focused on enhancing the health and wellness of millions of consumers who can benefit from its premium suite of organic, sustainable and non-GMO mushroom and mushroom-infused formulations.

Champignon Brands (CSE: SHRM) has positioned itself to rapidly become a global force as a vertically integrated producer of artisanal medicinal mushrooms and associated products. The Champignon team is focused on enhancing the health and wellness of millions of consumers who can benefit from its premium suite of organic, sustainable and non-GMO mushroom and mushroom-infused formulations.

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canadian‐based exploration company focused on the acquisition and development of production grade cobalt and nickel deposits, key raw material inputs for the growing lithium‐ion battery industry.

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canadian‐based exploration company focused on the acquisition and development of production grade cobalt and nickel deposits, key raw material inputs for the growing lithium‐ion battery industry.

SRAX (NASDAQ: SRAX) is a digital-marketing and consumer-data-management technology company. SRAX's technology unlocks data to reveal brands' core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX's tools deliver a digital competitive advantage for brands in the CPG, automotive, investor-relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX (NASDAQ: SRAX) is a digital-marketing and consumer-data-management technology company. SRAX's technology unlocks data to reveal brands' core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX's tools deliver a digital competitive advantage for brands in the CPG, automotive, investor-relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

Plus Products (CSE: PLUS) (OTCQX: PLPRF) is a hemp and cannabis food company focused on using nature to bring balance to consumers' lives. PLUS's mission is to make cannabis safe and approachable, beginning with high-quality products that deliver consistent consumer experiences. PLUS is headquartered in San Mateo, California, and has 80 employees. For more information, visit the company's website at www.PlusProductsInc.com.

MCTC Holdings Inc. (MCTC), doing business as Cannabis Global Inc., is focused on delivering long-term shareholder growth and results. The company invests with confidence and determination to be the forefront of the cannabis and CBD revolution.

Trxade Group (NASDAQ: MEDS) (OTCQB: TRXD) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals, accessories and services. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; the Trxade B2B trading platform with 11,000 registered pharmacies, licensed virtual Wholesale and Mail Order Pharmacy capabilities including DelivMeds, as well as the newly acquired assets of Bonum Health.

Sigma Labs (NASDAQ: SGLB) is an emerging provider of quality-assurance software to the commercial 3D-printing industry under the PrintRite3D brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection (“CAI”) solutions known as PrintRite3D for 3D, advanced-manufacturing technologies. Sigma Labs' advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time.

No Borders (OTC: NBDR) is a multifaceted corporation specializing in the acquisition, creation and scaling of commercial and consumer products by utilizing cutting-edge technologies to reduce costs while increasing revenues and shareholder value through technological superiority across its portfolio of assets.

Wonderfilm (OTCQB: WDRFF) (TSX.V: WNDR) is a leading entertainment company with production offices in Los Angeles and corporate offices in Vancouver. The company's core business is producing market-driven independent feature films and quality television series for multi-platform global exploitation. Wonderfilm is a producer and distributor only for the projects disclosed. The legal ownership of movie productions is held in a special purpose legal entity held at arm's length to the company to facilitate for the qualification of various levels of domestic and foreign government tax credit incentives that are customary in the film and production business.